
¹ßÇ¥Çß´Ù (NEJM 35-17 Oct 21, 2004) [±Ù°Å] October 20, 2004 Medscape Medical News Deborah Flapan; Vioxx Withdrawal Prompts Reevaluation of COX-2 Inhibitor Safety ; the New England Journal of Medicine, Garret A. Fitz...

La compa

enough evidence of that to send out any alarms. Q: What's the lesson from the Vioxx episode? The withdrawal of Vioxx and Bextra from the market led to significant changes in the way drugs are regulated in the United...

into question the expectations investors have regarding any yet-to-be-approved drug. Since 2004's Vioxx withdrawal, the FDA has been under pressure to be more safety-minded. A go-ahead is never guaranteed. And compa...

consumers contending the painkiller Vioxx caused heart attacks and strokes. The safety problems of Vioxx and the withdrawal of Vioxx from the market was a watershed event in regulating prescription drugs in the U.S.

The drugmaker said it would still defend all claims not included in the settlement. Since the withdrawal of Vioxx, Merck has won 11 court cases over the drug and lost five. While it is appealing those cases that...

pay fees to the agency to defray the cost of reviewing new medicines. But in the wake of the Vioxx withdrawal, lawmakers seized on the bill to overhaul how the FDA handles the safety of the drugs it regulates. Drug...

to the battered drug company it was three years ago. The stock is up 12 percent from its pre-Vioxx withdrawal levels. Quick Vote Do you agree with our take on Merck's stock? Yes No or View results Video More video...

through product package inserts. However, drug withdrawals such as the highly publicized Vioxx withdrawal in 2004 brought the FDA under scrutiny and highlighted the need for fundamental changes in the system. Scope...

layoff notices to nearly 2,000 of its employees. That now appears unlikely. In the wake of the Vioxx withdrawal and subsequent problems with other drugs, lawmakers seized on the legislation to overhaul how the FDA...